A pharmacokinetic study of ampiroxicam.

概要

論文の詳細を見る
The pharmacokinetics of ampiroxicam, a prodrug of piroxicam, were investigated by a crossover study involving 19 healthy normal subjects which was conducted over two different phases. In the 1st phase of the study, the pharmacokinetics were compared between a dose of 27 mg and 20 mg of ampiroxicam and in the 2 nd phase, doses of 27 mg and 13.5 mg ampiroxicam were compared with a dose of 20 mg of piroxicam with the results sum-marized below. Both the Cmax and AUC following administration of ampiroxicam were dose-dependent. The ampiroxicam 27 mg group was found to be slower in the absorption rate and slightly lower in Cmax than the piroxicam 20 mg group. But the ADCs of the drug groups were equal indicating that ampiroxicam and piroxicam were bioequivalent. The half-lives of ampiroxicam and piroxicam were approximately 40 hours. Neither adverse reactions nor laboratory abnormalities were noted during the present study.
日本炎症・再生医学会の論文